Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Reactive intermediate deaminase A (RidA) is an evolutionarily conserved enzyme found in bacteria, archaea, and eukaryotes. RidA belongs to the Rid (YjgF/YER057c/UK114) superfamily and catalyzes the hydrolysis (deamination) of reactive enamine and imine intermediates, such as 2-aminoacrylate, generated by pyridoxal 5'-phosphate (PLP)-dependent enzymatic reactions. These intermediates, if not rapidly detoxified, can inactivate other essential PLP-dependent enzymes, leading to metabolic damage. By converting unstable and potentially harmful intermediates to stable keto acids, RidA safeguards cellular metabolism and supports amino acid biosynthesis. In addition to its primary enzymatic role, RidA has been reported to display molecular chaperone activity during oxidative stress and may possess ribonuclease or translational inhibition functions in some homologs, especially in higher eukaryotes. RidA dysfunction or deficiency has pleiotropic cellular impacts, and variants have been linked to altered amino acid biosynthesis, stress responses, and possibly cancer progression[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Reactive intermediate deaminase A (RidA).